Thelansis

  Chronic lymphocytic leukemia (CLL) is a cancer affecting the blood and bone marrow, where blood cells are produced. It is the most common type of adult leukemia and is characterized by a distinct immunophenotype involving CD19+, CD20+, CD5+, CD23+, and surface immunoglobulin (sIg)-positive cells. While the exact cause of CLL in most patients is unknown, approximately 8% to 10% have a first-degree relative with the diagnosis. Initial therapy typically yields complete or partial responses in most patients, but it is not curative, often leading to relapse. Many individuals may need a change in treatment due to intolerance. Relapse is defined as CLL progression after achieving partial or complete remission for at least 6 months, differing from refractoriness, which indicates non-response to treatment, progression during therapy, or progression within 6 months of completing a time-limited treatment. Approximately one-third of patients never require treatment and succumb to unrelated...